Literature DB >> 24688600

Intralesional collagenase in the treatment of Peyronie's disease.

Stanton C Honig1.   

Abstract

The objective of intralesional pharmacotherapy in the treatment of Peyronie's disease is to deliver large doses of pharmacologic agents that can have a local effect on wound remodeling, with minimal side effects. Guidelines for the treatment of peyronie's disease published in the Journal of Sexual Medicine and the European Association of Urology offer no grade A evidence of efficacy with multiple agents such as steroids, verapamil and interferon. Intralesional collagenase is the first drug to be approved by the United States Food and Drug Administration for the treatment of Peyronie's disease. This is based on grade A evidence. The purpose of this update is to review the literature and current data on intralesional collagenase in the treatment of Peyronie's disease.

Entities:  

Keywords:  Peyronie’s disease; collagenase; intralesional

Year:  2014        PMID： 24688600      PMCID： PMC3943365          DOI： 10.1177/1756287213509849

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN： 1756-2872


  12 in total

1.  The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman.

Authors:  Sidney Glina; Martin K Gelbard; Emre Akkus; Gerald H Jordan; Laurence A Levine
Journal:  J Sex Med       Date:  2007-09       Impact factor: 3.802

2.  Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.

Authors:  Martin Gelbard; Larry I Lipshultz; James Tursi; Ted Smith; Greg Kaufman; Laurence A Levine
Journal:  J Urol       Date:  2012-04-13       Impact factor: 7.450

3.  Chemonucleolysis (discolysis) with collagenase.

Authors:  M D Brown; J S Tompkins
Journal:  Spine (Phila Pa 1976)       Date:  1986-03       Impact factor: 3.468

Review 4.  EAU guidelines on penile curvature.

Authors:  Konstantinos Hatzimouratidis; Ian Eardley; François Giuliano; Dimitrios Hatzichristou; Ignacio Moncada; Andrea Salonia; Yoram Vardi; Eric Wespes
Journal:  Eur Urol       Date:  2012-05-25       Impact factor: 20.096

5.  Collagenase for Peyronie's disease experimental studies.

Authors:  M K Gelbard; R Walsh; J J Kaufman
Journal:  Urol Res       Date:  1982

Review 6.  Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.

Authors:  Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson
Journal:  J Urol       Date:  2013-01-31       Impact factor: 7.450

7.  Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire.

Authors:  Wayne J G Hellstrom; Robert Feldman; Raymond C Rosen; Ted Smith; Gregory Kaufman; James Tursi
Journal:  J Urol       Date:  2013-01-31       Impact factor: 7.450

8.  The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.

Authors:  Gerald H Jordan
Journal:  J Sex Med       Date:  2008-01       Impact factor: 3.802

9.  The use of collagenase in the treatment of Peyronie's disease.

Authors:  M K Gelbard; A Lindner; J J Kaufman
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

10.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Authors:  Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245
View more
  4 in total

1.  Pharmaceutical biotechnological potential of filamentous fungi isolated from textile industry.

Authors:  Suzan Prado Fernandes Bernal; Micaela Andrea Gritti; Viviane Piccin Dos Santos; Júlia Ronzella Ottoni; Valéria Maia de Oliveira; Maria Elisa Peichoto; Michel Rodrigo Zambrano Passarini
Journal:  Arch Microbiol       Date:  2021-05-21       Impact factor: 2.552

2.  Matrix metalloproteinases as reagents for cell isolation.

Authors:  Anna M Knapinska; Sabrina Amar; Zhong He; Sandro Matosevic; Claudia Zylberberg; Gregg B Fields
Journal:  Enzyme Microb Technol       Date:  2016-07-20       Impact factor: 3.493

3.  Complementary Proteomic and Biochemical Analysis of Peptidases in Lobster Gastric Juice Uncovers the Functional Role of Individual Enzymes in Food Digestion.

Authors:  Betsaida Bibo-Verdugo; Anthony J O'Donoghue; Liliana Rojo-Arreola; Charles S Craik; Fernando García-Carreño
Journal:  Mar Biotechnol (NY)       Date:  2015-11-27       Impact factor: 3.619

4.  Predictors of Pursuing Intralesional Xiaflex in Peyronie's Disease Patients.

Authors:  Nahid Punjani; Bruno Nascimento; Carolyn Salter; Jose Flores; Eduardo Miranda; Jean Terrier; Hisanori Taniguchi; Lawrence Jenkins; John P Mulhall
Journal:  J Sex Med       Date:  2021-07-03       Impact factor: 3.937
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.